Answer :
A. Check the results of the patient's most recent CBC
Rationale: The client may have anemia as a result of myelosuppression (bone marrow suppression) from the chemotherapy.Cisplatin-based chemotherapy has conventionally been the first-line (1L) treatment for patients with locally advanced and metastatic urothelial cancer (mUC) of the bladder. This treatment has resulted in overall survival (OS) benefit, with median OS of 13 to 15 months and approximately 15% long-term responses.FIRST-LINE THERAPY A cisplatin-based combination chemotherapy regimen is the preferred initial therapy for patients with metastatic urothelial cancer of the bladder and urinary tract who are cisplatin candidates.The most common regimens for systemic, or whole-body, chemotherapy to treat bladder cancer include:
Cisplatin and gemcitabine.
Carboplatin (available as a generic drug) and gemcitabine.
MVAC, which combines 4 drugs: methotrexate (Rheumatrex, Trexall), vinblastine (Velban), doxorubicin, and cisplatin.
Find out more about bladder cancer
brainly.com/question/28841362
#SPJ4